These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 17938845

  • 1. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice.
    Middleton ET, Steel SA, Doherty SM.
    Calcif Tissue Int; 2007 Nov; 81(5):335-40. PubMed ID: 17938845
    [Abstract] [Full Text] [Related]

  • 2. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 4. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
    Eastell R, Krege JH, Chen P, Glass EV, Reginster JY.
    Curr Med Res Opin; 2006 Jan; 22(1):61-6. PubMed ID: 16393431
    [Abstract] [Full Text] [Related]

  • 5. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [Abstract] [Full Text] [Related]

  • 6. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 7. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
    Minne H, Audran M, Simões ME, Obermayer-Pietsch B, Sigurðsson G, Marín F, Dalsky GP, Nickelsen T, EUROFORS Study Group.
    Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
    [Abstract] [Full Text] [Related]

  • 8. Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.
    Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S.
    Calcif Tissue Int; 2011 Aug; 89(2):130-9. PubMed ID: 21626160
    [Abstract] [Full Text] [Related]

  • 9. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM, Paschalis EP, Blouin S, Fratzl-Zelman N, Klaushofer K, Roschger P.
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [Abstract] [Full Text] [Related]

  • 10. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A, Constancio L, Fogelman I, Hampson G.
    BMC Musculoskelet Disord; 2007 Jan 10; 8():3. PubMed ID: 17214897
    [Abstract] [Full Text] [Related]

  • 11. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
    Middleton ET, Steel SA, Aye M, Doherty SM.
    J Bone Miner Res; 2010 Mar 10; 25(3):455-62. PubMed ID: 20201000
    [Abstract] [Full Text] [Related]

  • 12. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
    Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ.
    Bone; 2005 Jun 10; 36(6):948-58. PubMed ID: 15878318
    [Abstract] [Full Text] [Related]

  • 13. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A.
    J Bone Miner Metab; 2020 May 10; 38(3):310-315. PubMed ID: 31707465
    [Abstract] [Full Text] [Related]

  • 14. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.
    J Bone Miner Res; 2013 Jan 10; 28(1):196-205. PubMed ID: 22836585
    [Abstract] [Full Text] [Related]

  • 15. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, EUROFORS Investigators.
    J Clin Endocrinol Metab; 2008 Mar 10; 93(3):852-60. PubMed ID: 18160462
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF.
    Arch Intern Med; 2008 Mar 10; 165(15):1762-8. PubMed ID: 16087825
    [Abstract] [Full Text] [Related]

  • 18. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
    Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators.
    J Bone Miner Res; 2008 Oct 10; 23(10):1591-600. PubMed ID: 18505369
    [Abstract] [Full Text] [Related]

  • 19. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E.
    Horm Metab Res; 2009 Jul 10; 41(7):559-62. PubMed ID: 19204890
    [Abstract] [Full Text] [Related]

  • 20. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.
    Sridharan M, Cheung J, Moore AE, Frost ML, Fraser WD, Fogelman I, Hampson G.
    Calcif Tissue Int; 2010 Nov 10; 87(5):398-405. PubMed ID: 20838781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.